Drugs / HRS-4729
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07807059 | Sep 2026 → Mar 2027 expected | metabolic dysfunction-associated steatotic liver disease, obesity disorder, type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06762600 | Jan 2025 → Mar 2026 | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07843862 | Oct 2026 → Apr 2027 expected | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07690826 | Jul 2026 → Mar 2027 expected | obesity disorder | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07660848 | Jul 2026 → Mar 2028 expected | metabolic dysfunction-associated steatohepatitis | Fujian Shengdi Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | Kailera | Results Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting kailera.com ↗
HRS-4729 and ribupatide injection demonstrated favorable safety and tolerability data consistent with GLP-1-based treatments. |
| 2026-05-28 | Jiangsu HengRui Medicine Co., Ltd. | Results 恒瑞医药披露GLP-1/GIP/GCG三重受体激动剂HRS-4729注射液中国Ⅰ期首次人体研究积极顶线结果 hengrui.com ↗
在Ⅰ期多次剂量递增（MAD）试验中，HRS-4729组平均体重较基线降幅最高达16.0%，并可降低肝脏脂肪含量，安全性和耐受性特征与现有GLP-1类药物类似。 |
| 2026-05-26 | Kailera | Results Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates kailera.com ↗
We are also pleased to announce new topline data for HRS-7535 (KAI-7535) and HRS-4729 (KAI-4729) that reflect the shared commitment with our partner to advance a diverse portfolio with multiple mechanism |
| 2025-09-16 | Jiangsu HengRui Medicine Co., Ltd. | Regulatory 恒瑞1类创新药GLP-1R/GIPR/GCGR三受体激动剂HRS-4729用于代谢相关脂肪性肝病/代谢相关脂肪性肝炎获批临床 hengrui.com ↗
近日，恒瑞医药及子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意恒瑞自主研发的1类创新药HRS-4729注射液在代谢相关脂肪性肝病/代谢相关脂肪性肝炎患者群体中开展临床试验。 |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-01 | Kailera | Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting kailera.com ↗ |
| 2026-05-28 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞医药披露GLP-1/GIP/GCG三重受体激动剂HRS-4729注射液中国Ⅰ期首次人体研究积极顶线结果 hengrui.com ↗ |
| 2026-05-26 | Kailera | Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates kailera.com ↗ |
| 2025-09-16 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞1类创新药GLP-1R/GIPR/GCGR三受体激动剂HRS-4729用于代谢相关脂肪性肝病/代谢相关脂肪性肝炎获批临床 hengrui.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-4729 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06762600 ↗ |
| Route | Subcutaneous | “Single and Multiple Subcutaneous Injections of HRS-4729 Injection” NCT06762600 ↗ |